Want to see AU:CBL full AI Analyst Report?

Control Bionics Ltd. (CBL) Price & Analysis

3 Followers

CBL Stock Chart & Stats

AU$0.06

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.06

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.03 - AU$0.10

Previous CloseN/A

Volume65.91K

Average Volume (3M)234.31K

Market Cap

AU$30.47M

Enterprise ValueAU$29.03M

Total Cash (Recent Filing)AU$2.08M

Total Debt (Recent Filing)AU$618.92K

Price to Earnings (P/E)―

Beta-0.04

Next Earnings

Feb 24, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding544,132,800

10 Day Avg. Volume250,664

30 Day Avg. Volume234,311

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)4.35

Price to Sales (P/S)5.76

P/FCF Ratio-4.77

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Assistive Technology FocusCBL operates in a specialized assistive-technology niche addressing communication and digital-control needs for people with severe disabilities. Its EMG and related interface solutions could support differentiated positioning where user-specific functionality and accessibility are important.

Low Financial LeverageA relatively low debt burden reduces balance-sheet pressure and limits the immediate risk that interest obligations constrain operations. This conservative capital structure gives CBL more flexibility than a highly leveraged business while it works to improve profitability and cash generation.

Human-machine Interface CapabilityCBL’s products address a core functional need by converting user input into control of computers, communication devices, and digital systems. That role in enabling independence can support continued relevance of the product platform across its targeted disability market.

Bears Say

Revenue DeteriorationThe recent revenue decline, following a volatile performance history, indicates that CBL has not yet established a consistently expanding commercial base. Sustained contraction could reduce operating scale, weaken investment capacity, and make a path to breakeven more difficult.

Persistent UnprofitabilityLarge recurring operating and net losses show that the current business model is not covering its cost base. The move to a negative gross margin is especially concerning because it suggests product-level economics are under pressure, making durable profitability harder to achieve.

Negative Cash GenerationConsistently negative operating and free cash flow means CBL is not funding operations from internally generated cash. Continued cash outflows increase reliance on external capital and can limit the company’s ability to invest in products, sales growth, or market expansion.

Control Bionics Ltd. News

Control Bionics Issues Over 1 Million New Shares While Confirming Regulatory Compliance

Control Bionics Ltd. ( ($AU:CBL) ) has issued an announcement. Control Bionics Limited has issued 1,044,087 fully paid...

3d ago

CBL

Control Bionics Director Boosts Stake Through Equity-Based Fees

Control Bionics Ltd. ( ($AU:CBL) ) has issued an announcement. Control Bionics director Stephen Rix has increased his...

3d ago

CBL

Control Bionics Wins Strong Shareholder Backing at 2026 AGM

Control Bionics Ltd. ( ($AU:CBL) ) just unveiled an announcement. Control Bionics Limited held its Annual General Meeting...

9d ago

CBL

Control Bionics Moves From Foundations to Commercial Conversion

Control Bionics Ltd. ( ($AU:CBL) ) has provided an announcement. Control Bionics Ltd., listed on the ASX as...

10d ago

CBL

Control Bionics Options Expire, Trimming Potential Dilution

Control Bionics Ltd. ( ($AU:CBL) ) has issued an update. Control Bionics Limited has notified the market that...

11d ago

CBL

Control Bionics Wins CE Mark for NeuroStrip, Expanding Access Across Europe

The latest announcement is out from Control Bionics Ltd. ( ($AU:CBL) ). Control Bionics has secured CE marking...

18d ago

CBL

Control Bionics flags ASX Listing Rule breach over Phoenix loan facility

An announcement from Control Bionics Ltd. ( ($AU:CBL) ) is now available. Control Bionics has disclosed that it...

24d ago

CBL

Control Bionics Sets October Date for 2026 AGM and Moves to Digital Meeting Materials

An announcement from Control Bionics Ltd. ( ($AU:CBL) ) is now available. Control Bionics Limited has called its...

1M ago

CBL

Control Bionics Sets 2026 AGM to Vote on Board, Incentive Plans and Extra Capital Capacity

An update from Control Bionics Ltd. ( ($AU:CBL) ) is now available. Control Bionics Limited has convened its...

1M ago

CBL

Control Bionics Issues 1.6 Million Unquoted XV Options

An update from Control Bionics Ltd. ( ($AU:CBL) ) is now available. Control Bionics Limited has notified the...

2M ago

CBL

CBL FAQ

What was Control Bionics Ltd.’s price range in the past 12 months?

Control Bionics Ltd. lowest share price was AU$0.03 and its highest was AU$0.10 in the past 12 months.

What is Control Bionics Ltd.’s market cap?

Control Bionics Ltd.’s market cap is AU$30.47M.

When is Control Bionics Ltd.’s upcoming earnings report date?

Control Bionics Ltd.’s upcoming earnings report date is Feb 24, 2027 which is in 125 days.

How were Control Bionics Ltd.’s earnings last quarter?

Control Bionics Ltd. released its earnings results on Aug 27, 2026. The company reported -AU$0.009 earnings per share for the quarter.

Is Control Bionics Ltd. overvalued?

According to Wall Street analysts Control Bionics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Control Bionics Ltd. pay dividends?

Control Bionics Ltd. does not currently pay dividends.

What is Control Bionics Ltd.’s EPS estimate?

Control Bionics Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Control Bionics Ltd. have?

Control Bionics Ltd. has 544,132,800 shares outstanding.

What happened to Control Bionics Ltd.’s price movement after its last earnings report?

Control Bionics Ltd. reported an EPS of -AU$0.009 in its last earnings report. Following the earnings report the stock price went down -3.333%.

Which hedge fund is a major shareholder of Control Bionics Ltd.?

Currently, no hedge funds are holding shares in AU:CBL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Control Bionics Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-103.48%

Trailing 12-Months

Asset Growth

9.89%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Control Bionics Ltd.

Operating in Australia and North America, Control Bionics Limited and its subsidiaries specialize in the innovation, development, and market introduction of sophisticated assistive communication technologies. The company's offerings include the NeuroNode Trilogy and NeuroNode3 systems, which empower individuals facing speech and mobility challenges to control computers for speech generation, electronic correspondence, leisure activities, and remote operation of other devices. Control Bionics also provides Cosmos Connect, a versatile interface capable of managing diverse equipment like wheelchairs, robotic dining aids, and gaming consoles. Additionally, they offer Uno Touch, a dedicated speech-generating device, alongside various other sensors for a broad spectrum of uses. Founded in 2005, the entity was initially named Control Bionics Holdings Pty Limited before rebranding as Control Bionics Limited in September 2020. The company's base of operations is situated in Camberwell, Australia.